FXEMPIRE
All
Ad
Advertisement
Advertisement
Vladimir Zernov
Add to Bookmarks
Moderna

Moderna Video 13.04.21.

Moderna Says That Its Vaccine Is Not Linked To Rare Blood Clots

Shares of Moderna gained solid upside momentum after the company stated that available safety data on its coronavirus vaccine did not suggest an association with cerebral venous sinus thrombosis (CVST) or thrombotic events. More than 64.5 million doses of Moderna’s vaccine have been administered globally.

Advertisement
Know where the Market is headed? Take advantage now with 

Trading Derivatives carries a high level of risk to your capital and you should only trade with money you can afford to lose. Trading Derivatives may not be suitable for all investors, so please ensure that you fully understand the risks involved, and seek independent advice if necessary. A Product Disclosure Statement (PDS) can be obtained either from this website or on request from our offices and should be considered before entering into a transaction with us. Raw Spread accounts offer spreads from 0.0 pips with a commission charge of USD $3.50 per 100k traded. Standard account offer spreads from 1 pips with no additional commission charges. Spreads on CFD indices start at 0.4 points. The information on this site is not directed at residents in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

Moderna decided to issue this statement after U.S. recommended to pause the use of Johnson & Johnson COVID-19 vaccine as six women developed blood clots after receiving the vaccine. Previously, AstraZeneca faced problems with rare blood clots, and some countries decided to limit the use of the company’s vaccine.

While blood clots appear to be a very rare side effect (more than 6.8 million doses of Johnson & Johnson’s vaccine have been administered in the U.S., and only six cases of blood clots potentially linked to vaccine have been reported so far), Johnson & Johnson’s vaccine will surely suffer a PR blow.

This is a negative development for the mass vaccination program but a positive development for Moderna which may gain additional market share due to problems of AstraZeneca and Johnson & Johnson.

Advertisement

What’s Next For Moderna?

The bull case for Moderna is getting stronger. Its coronavirus vaccine has avoided any notable problems, and the company’s shares stand ready to gain from the problems of its competitors.

Currently, analysts expect that the company will report earnings of $21.85 per share in 2021 and $14.87 per share in 2022 so the stock is trading at about 10 forward P/E for 2022.

However, it is not clear whether revenue from the coronavirus vaccine will be recurring. If data suggests that people will need regular vaccinations, like in the case of an ordinary flu, Moderna shares will look very cheap at current levels.

In the near term, Moderna stock will likely continue to benefit from Johnson & Johnson and AstraZeneca problems.

For a look at all of today’s economic events, check out our economic calendar.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker